SPRY4 and breast carcinoma: If the presence of the original unaltered version of Spry4 in these mesenchymal-derived cell types has had a barely perceptible effect, it is an effective inhibitor of cell proliferation and migration in breast cancer [22] and glioblastoma-derived cells [19].